journal
MENU ▼
Read by QxMD icon Read
search

Journal of Viral Hepatitis

journal
https://www.readbyqxmd.com/read/28107601/predictors-of-liver-histological-changes-and-a-sustained-response-to-peginterferon-among-chronic-hepatitis-b-e-antigen-positive-patients-with-normal-or-minimally-elevated-alanine-aminotransferase-levels
#1
Jie Chen, Cheng-Run Xu, Min Xi, Wei-Wei Hu, Zheng-Hao Tang, Guo-Qing Zhang
BACKGROUND: A proportion of chronic hepatitis B (CHB) patients with normal or only minimally elevated ALT levels display significant histologic changes, and would benefit from antiviral therapy. OBJECTIVES: We aim to evaluate the histologic abnormalities seen in these patients, and then determine which of them would most likely respond to peginterferon therapy. METHODS: One hundred and thirteen hepatitis B e antigen (HBeAg)-positive patients with a normal or minimally elevated ALT level and moderate to severe histologic changes in their liver tissue were selected to receive peginterferon monotherapy and participate in a followup analysis...
January 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28107589/serum-lincrna-p21-as-a-potential-biomarker-of-liver-fibrosis-in-chronic-hepatitis-b-patients
#2
Fujun Yu, Guangyao Zhou, Kate Huang, XuFei Fan, Guojun Li, Bicheng Chen, Peihong Dong, Jianjian Zheng
Serum long non-coding RNAs (lncRNAs) are emerging as promising biomarkers for various human diseases. The aim of this study was to investigate the feasibility of using serum long intergenic non-coding RNA-p21 (lincRNA-p21) as a biomarker for chronic hepatitis B patients. Serum lincRNA-p21 levels were quantified using real-time PCR in 417 CHB patients and 363 healthy controls. The promoter methylation level of lincRNA-p21 was detected using bisulfite-sequencing analysis in primary hepatic stellate cells (HSCs)...
January 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28107583/chronic-hepatitis-c-and-chronic-kidney-disease-advances-limitations-and-unchartered-territories
#3
Manuel Mendizabal, K Rajender Reddy
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and effective with sustained virologic response (SVR) rates of >90% in most patients. Unique issues yet remain such as the challenges in patients with impaired renal function or decompensated cirrhosis. Patients with stage 4-5 chronic kidney disease (CKD) have a higher prevalence of HCV infection compared with the general population...
January 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28092420/immune-modulation-by-the-hepatitis-c-virus-core-protein
#4
Cecilia Fernández-Ponce, Juan Pedro Muñoz-Miranda, Mikel M Arbulo-Echevarria, Rocío Litrán, Enrique Aguado, Francisco García-Cozar
Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral persistence. Several HCV viral proteins have been described as immune modulators. In this review, we will focus on the effect of HCV nucleocapsid core protein in the function of immune cells and its correlation with the findings observed in HCV chronically infected patients...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28092419/improving-access-to-health-care-for-chronic-hepatitis-b-among-migrant-chinese-populations-a-systematic-mixed-methods-review-of-barriers-and-enablers
#5
Alicia Vedio, Eva Zhi Hong Liu, Andrew Ck Lee, Sarah Salway
Migrant Chinese populations in Western countries have a high prevalence of chronic hepatitis B but often experience poor access to healthcare and late diagnosis. This systematic review aimed to identify obstacles and supports to timely and appropriate health service use among these populations. Systematic searches resulted in 48 relevant studies published between 1996 and 2015. Data extraction and synthesis were informed by models of healthcare access that highlight the interplay of patient, provider and health system factors...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28092416/persistence-of-antibody-to-hepatitis-a-virus-20-years-after-receipt-of-hepatitis-a-vaccine-in-alaska
#6
Ian D Plumb, Lisa R Bulkow, Michael G Bruce, Thomas W Hennessy, Julie Morris, Karen Rudolph, Philip Spradling, Mary Snowball, Brian J McMahon
Hepatitis A vaccine is recommended for children ≥1 year old to prevent hepatitis A virus (HAV) infection. However the duration of vaccine-induced immunity is unknown. We evaluated a cohort of Alaska Native persons 20 years after HAV vaccination. Children aged 3-6 years had been previously randomized to receive 3 doses of HAV vaccine (360 ELISA units/dose) at: A) 0,1,2 months; B) 0,1,6 months; and C) 0,1,12 months. We measured anti-HAV antibody concentrations every 2-3 years; described geometric mean concentrations (GMC) and the proportion with protective antibody (≥20 mIU mL-1) over time; and modelled change in GMC using fractional polynomial regression...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28092412/population-dynamics-of-hcv-subtypes-in-injecting-drug-users-on-methadone-maintenance-treatment-in-china-associated-with-economic-and-health-reform
#7
Sheng Zhou, Eleonora Cella, Wang Zhou, Wen-Hua Kong, Man-Qing Liu, Pu-Lin Liu, Massimo Ciccozzi, Marco Salemi, Xin-Guang Chen
The extensive genetic heterogeneity of hepatitis C virus (HCV) requires in-depth understanding of the population dynamics of different viral subtypes for more effective control of epidemic outbreaks. We analyzed HCV sequences data from 125 participants in Wuhan, China. These participants were newly infected by subtype 1b (n=13), 3a (n=15), 3b (n=50), and 6a (n=39) while on methadone maintenance treatment (MMT). Bayesian phylogenies and demographic histories were inferred for these subtypes. Participants infected with HCV-1b and 3a were clustered in well-supported monophyletic clades, indicating local sub-epidemics...
January 16, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28072494/hepatitis-b-virus-reactivation-in-breast-cancer-patients-undergoing-chemotherapy-a-review-and-meta-analysis-of-prophylaxis-management
#8
Zihao Liu, Lei Jiang, Gehao Liang, Erwei Song, Yubao Zheng, Chang Gong
BACKGROUND & AIMS: Hepatitis B virus (HBV) reactivation during or after chemotherapy in breast cancer patients has become a remarkable clinical problem. Prophylactic nucleos(t)ide analogues (NAs) are recommended for breast cancer patients who are hepatitis B surface antigen (HBsAg) positive before chemotherapy. We performed an up-to-date meta-analysis to compare the efficacy of prophylactic lamivudine use with non-prophylaxis in HBsAg positive breast cancer patients undergoing chemotherapy...
January 10, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28039935/a-systematic-model-improves-hepatitis-c-virus-birth-cohort-screening-in-hospital-based-primary-care
#9
Aparna Goel, Jennifer Sanchez, Lismeiry Paulino, Colin Feuille, Jonathan Arend, Brijen Shah, Douglas Dieterich, Ponni V Perumalswami
Despite national and local governing board recommendations in the United States of America to perform an HCV screening test in baby boomers, screening rates remain low. Our goal was to study the impact of an HCV screening and link to care program with patient navigation in two New York City primary care practices. This was a two-year prospective study of patients born between 1945-1965 ("baby boomers") with encounters at two primary care practices at the Mount Sinai Hospital between November 1, 2013 and November 30, 2015...
December 31, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28039923/impact-of-treatment-on-hepatitis-c-virus-transmission-and-incidence-in-egypt-a-case-for-treatment-as-prevention
#10
Houssein Ayoub, Laith J Abu-Raddad
Egypt has launched a hepatitis C virus (HCV) treatment program using direct-acting antivirals (DAAs). Our aim was to assess impact of five plausible program scale-up and sustainability scenarios for HCV treatment as prevention in Egypt. We developed and analyzed a mathematical model to assess program impact using epidemiologic, programming and health economics measures. The model was parametrized with current and representative natural history, HCV prevalence and program data. HCV incidence in Egypt is declining, but will persist at a considerable level for decades unless controlled by interventions...
December 31, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28039902/long-term-safety-and-efficacy-of-telbivudine-in-infants-born-to-mothers-treated-during-the-second-or-third-trimesters-of-pregnancy
#11
Guo-Rong Han, Hong-Xiu Jiang, Cui-Min Wang, Yi Ding, Gen-Ju Wang, Xin Yue, Liu Zhou, Wei Zhao
Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year. This study evaluated the long-term efficacy and safety of telbivudine in 214 infants born to 210 pregnant women with chronic hepatitis B infection who were treated with telbivudine during pregnancy (weeks 20-32 of gestation). The infants were followed for up to 5 years after birth. The efficacy endpoint was the rate of perinatal transmission, which was established by HBsAg and HBV DNA levels at 7 and 12 months...
December 31, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28027424/hcv-reinfection-incidence-among-individuals-treated-for-recent-infection
#12
Marianne Martinello, Jason Grebely, Kathy Petoumenos, Edward Gane, Margaret Hellard, David Shaw, Joe Sasadeusz, Tanya L Applegate, Gregory J Dore, Gail V Matthews
BACKGROUND AND AIMS: One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this analysis was to calculate the incidence of HCV reinfection among both HIV-positive and negative individuals treated for recent HCV infection (estimated infection duration <18 months). METHODS: Individuals with recent HCV infection who achieved an end-of-treatment response in four open-label studies between 2004 and 2015 in Australia and New Zealand were assessed for HCV reinfection, confirmed by sequencing of the Core-E2 and/or NS5B regions...
December 27, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28025872/lamivudine-therapy-during-the-second-vs-the-third-trimester-for-preventing-transmission-of-chronic-hepatitis-b
#13
C Q Pan, W Yi, M Liu, G Wan, Y-H Hu, M-F Zhou
There are little data on the timing of initiating lamivudine therapy for preventing transmission of hepatitis B in highly viremic mothers. Between May 2008 and January 2015, we retrospectively enrolled mothers with HBV DNA >6 log10  copies/mL who received lamivudine during pregnancy, and we compared them to untreated mothers. The primary measurement was the vertical transmission rate. The secondary outcomes were the mothers' and infants' safety. Among 249 consecutive mothers enrolled, 66 and 94 received lamivudine during the second and third trimesters, respectively, and 89 were untreated...
December 26, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28012213/antibody-dependent-and-independent-uptake-of-hbsag-across-human-leukocyte-subsets-is-similar-between-individuals-with-chronic-hepatitis-b-virus-infection-and-healthy-donors
#14
Hugo Tharinger, Indrani Rebbapragada, Dharmaraj Samuel, Nikolai Novikov, Mindie Nguyen, Robert Jordan, Christian R Frey, Stefan Pflanz
Maintaining detectable levels of antibodies to hepatitis B surface antigen (HBsAg) in serum, i.e. HBsAg sero-conversion, is the key clinical endpoint indicative of recovery from infection with hepatitis B virus (HBV). HBV-infected hepatocytes secrete HBsAg sub-viral particles in vast excess over HBV virions. Therefore, detectable hepatitis B surface antibody (anti-HBs) titers imply complete elimination of HBV virions as well as HBsAg particles. Although intrahepatic phagocytes, e.g. Kupffer cells, are thought to mediate clearance of HBsAg via antibody (Ab)-dependent and -independent mechanisms, the relative contributions of circulating phagocytic cell types to HBsAg elimination are poorly characterized...
December 23, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27983762/differences-in-background-characteristics-of-patients-with-chronic-hepatitis-c-who-achieved-sustained-virologic-response-with-interferon-free-versus-interferon-based-therapy-and-the-risk-of-developing-hepatocellular-carcinoma-after-eradication-of-hepatitis
#15
H Toyoda, T Tada, K Takaguchi, T Senoh, N Shimada, A Hiraoka, K Michitaka, T Ishikawa, T Kumada
We compared the background characteristics of patients with chronic hepatitis C who achieved eradication of hepatitis C virus (HCV), that is sustained virologic response (SVR), with interferon (IFN)-based versus IFN-free antiviral therapy in Japan. In addition, we used a previously reported risk assessment model to compare the incidence of hepatocellular carcinoma (HCC) after SVR by treatment type. Pretreatment characteristics of 1533 patients who achieved SVR with IFN-based therapy and 1086 patients with IFN-free therapy from five institutions across Japan were compared...
December 16, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27976491/effectiveness-and-safety-of-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-an-early-access-programme-for-spanish-patients-with-genotype-1-4-chronic-hepatitis-c-virus-infection
#16
C Perelló, J A Carrión, B Ruiz-Antorán, J Crespo, J Turnes, J Llaneras, S Lens, M Delgado, J García-Samaniego, F García-Paredes, I Fernández, R M Morillas, D Rincón, J C Porres, M Prieto, M Lázaro Ríos, C Fernández-Rodríguez, J A Hermo, M Rodríguez, J I Herrero, P Ruiz, J R Fernández, M Macías, J M Pascasio, J M Moreno, M Á Serra, J Arenas, Y Real, F Jorquera, J L Calleja
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naïve and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27976490/therapy-with-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-is-effective-and-safe-for-the-treatment-of-genotype-1-and-4-hepatitis-c-virus-infection-hcv-in-patients-with-severe-renal-impairment-a-multicenter-experience
#17
Raquel Muñoz-Gómez, Diego Rincón, Adriana Ahumada, Eduardo Hernández, María José Devesa, Sonia Izquierdo, Maria Ortiz, Alicia Hernández-Albujar, Conrado Fernández-Rodríguez, Marta Calvo, Rosario González, Mar Lozano, Gregorio Castellano, Inmaculada Fernández-Vázquez
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15-29 mL/min/1...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27976461/safety-and-efficacy-of-direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-a-real-world-population-aged-65-years-and-older
#18
Fabio Conti, Stefano Brillanti, Federica Buonfiglioli, Ranka Vukotic, Maria Cristina Morelli, Claudine Lalanne, Marco Massari, Francesco Giuseppe Foschi, Veronica Bernabucci, Ilaria Serio, Gian Maria Prati, Elisa Negri, Lorenzo Badia, Paolo Caraceni, Paolo Muratori, Giovanni Vitale, Alberto Porro, Marta Morotti, Giuseppe Mazzella, Pietro Andreone
The availability of direct acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virological response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centers in Emilia Romagna (Italy) were enrolled...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27966249/cost-effectiveness-of-elbasvir-grazoprevir-use-in-treatment-naive-and-treatment-experienced-patients-with-hepatitis-c%C3%A2-virus-genotype-1-infection-and-chronic-kidney-disease-in-the-united-states
#19
E Elbasha, W Greaves, D Roth, C Nwankwo
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality and results in substantial healthcare costs. A once-daily oral regimen of elbasvir/grazoprevir (EBR/GZR) for 12 weeks was found to be a safe and efficacious treatment for HCV in patients with CKD. We evaluated the cost-effectiveness of EBR/GZR in treatment-naïve and treatment-experienced CKD patients compared with no treatment (NoTx) and pegylated interferon plus ribavirin (peg-IFN/RBV) using a computer-based model of the natural history of chronic HCV genotype 1 infection, CKD and liver disease...
December 13, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27943542/hbv-hcv-co-infection-is-associated-with-a-high-level-of-hcv-spontaneous-clearance-among-drug-users-and-blood-donors-in-china
#20
H Xiong, X Rong, M Wang, R Xu, K Huang, Q Liao, J Huang, J Chen, C Li, X Tang, Z Shan, M Zhang, K Nelson, Y Fu
Understanding the biology of spontaneous clearance of hepatitis C virus (HCV) infection could lead to improved strategies to prevent the sequelae associated with chronic HCV infection. Chronic infections with hepatitis virus are very common in China, but the factors associated with spontaneous clearance of HCV have not been adequately studied. We evaluated the spontaneous clearance of HCV among 1918 drug users and 1526 HCV-seropositive blood donors in Guangzhou, China. Among participants who were co-infected with hepatitis B virus (HBV), 41...
December 12, 2016: Journal of Viral Hepatitis
journal
journal
32017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"